“Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis”. SKIN The Journal of Cutaneous Medicine 4, no. 6 (October 27, 2020): s72. Accessed April 18, 2025. https://skin.dermsquared.com/skin/article/view/1105.